Targeting the CXCR4/CXCL12 axis with the peptide antagonist E5 to inhibit breast tumor progression

Signal Transduction and Targeted Therapy

Volumn 2, Issue , 2017, Pages

  Guo, Hua ^a   Ge, Yangyang ^a   Li, Xiaojin ^a   Yang, Yanlian ^b,c   Meng, Jie ^a   Liu, Jian ^a   Wang, Chen ^b,c   Xu, Haiyan ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY   (China)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85041705986     PISSN: 20959907     EISSN: 20593635     Source Type: Journal    
DOI: 10.1038/sigtrans.2017.33     Document Type: Article

References (37)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017; 67: 7–30.
2. Karayannopoulou M, Lafioniatis S. Recent advances on canine mammary cancer chemotherapy: A review of studies from 2000 to date. Rev Med Vet 2016; 167: 192–200.
3. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 2004; 14: 171–179.
4. Dewan MZ, Ahmed S, Iwasaki Y, Ohba K, Toi M, Yamamoto N. Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer. Biomed Pharmacother 2006; 60: 273–276.
5. Luker KE, Luker GD. Functions of CXCL12 and CXCR4 in breast cancer. Cancer Lett 2006; 238: 30–41.
6. Domanska UM, Kruizinga RC, Nagengast WB, Timmer-Bosscha H, Huls G, de Vries EG et al. A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer 2013; 49: 219–230.
7. Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 2009; 23: 43–52.
8. Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J et al. CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev 2010; 29: 709–722.
9. Debnath B, Xu S, Grande F, Garofalo A, Neamati N. Small molecule inhibitors of CXCR4. Theranostics 2013; 3: 47–75.
10. De Clercq E. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol 2009; 77: 1655–1664.
11. Williams SA, Harata-Lee Y, Comerford I, Anderson RL, Smyth MJ, McColl SR. Multiple functions of CXCL12 in a syngeneic model of breast cancer. Mol Cancer 2010; 9: 250.
12. Mercurio L, Ajmone-Cat MA, Cecchetti S, Ricci A, Bozzuto G, Molinari A et al. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model. J Exp Clin Cancer Res 2016; 35: 55.
13. Kim M, Koh YJ, Kim KE, Koh BI, Nam DH, Alitalo K et al. CXCR4 signaling regulates metastasis of chemoresistant melanoma cells by a lymphatic metastatic niche. Cancer Res 2010; 70: 10411–10421.
14. Guo F, Wang Y, Liu J, Mok SC, Xue F, Zhang W. CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks. Oncogene 2016; 35: 816–826.
15. Burger M, Glodek A, Hartmann T, Schmitt-Graff A, Silberstein LE, Fujii N et al. Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene 2003; 22: 8093–8101.
16. Mori T, Doi R, Koizumi M, Toyoda E, Ito D, Kami K et al. CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. Mol Cancer Ther 2004; 3: 29–37.
17. Hartmann TN, Burger JA, Glodek A, Fujii N, Burger M. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene 2005; 24: 4462–4471.
18. Yoon Y, Liang Z, Zhang X, Choe M, Zhu A, Cho HT et al. CXC chemokine receptor-4 antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models. Cancer Res 2007; 67: 7518–7524.
19. Liang Z, Wu T, Lou H, Yu X, Taichman RS, Lau SK et al. Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res 2004; 64: 4302–4308.
20. Peng SB, Zhang X, Paul D, Kays LM, Gough W, Stewart J et al. Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models. Mol Cancer Ther 2015; 14: 480–490.
21. Li X, Guo H, Yang Y, Meng J, Liu J, Wang C et al. A designed peptide targeting CXCR4 displays anti-acute myelocytic leukemia activity in vitro and in vivo. Sci Rep 2014; 4: 6610.
22. Li X, Guo H, Duan H, Yang Y, Meng J, Liu J et al. Improving chemotherapeutic efficiency in acute myeloid leukemia treatments by chemically synthesized peptide interfering with CXCR4/CXCL12 axis. Sci Rep 2015; 5: 16228.
23. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006; 107: 1761–1767.
24. Li J, Jiang K, Qiu XC, Li M, Hao Q, Wei L et al. Overexpression of CXCR4 is significantly associated with cisplatin-based chemotherapy resistance and can be a prognostic factor in e pithelial ovarian cancer. BMP Rep 2014; 47: 33–38.
25. Bergfeld SA, Blavier L, DeClerck YA. Bone marrow-derived mesenchymal stromal cells promote survival and drug resistance in tumor cells. Mol Cancer Therap 2014; 13: 962–975.
26. Otsuka S, Klimowicz AC, Kopciuk K, Petrillo SK, Konno M, Hao D et al. CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer. J Thorac Oncol 2011; 6: 1169–1178.
27. Zhang SS, Han ZP, Jing YY, Tao SF, Li TJ, Wang H et al. CD133(+)CXCR4(+) colon cancer cells exhibit metastatic potential and predict poor prognosis of patients. BMC Med 2012; 10: 85.
28. Sekiya R, Kajiyama H, Sakai K, Umezu T, Mizuno M, Shibata K et al. Expression of CXCR4 indicates poor prognosis in patients with clear cell carcinoma of the ovary. Hum Pathol 2012; 43: 904–910.
29. Scala S, Ottaiano A, Ascierto PA, Cavalli M, Simeone E, Giuliano P et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res 2005; 11: 1835–1841.
30. Konoplev S, Jorgensen JL, Thomas DA, Lin E, Burger J, Kantarjian HM et al. Phosphorylated CXCR4 is associated with poor survival in adults with B-acute lymphoblastic leukemia. Cancer 2011; 117: 4689–4695.
31. Zhao H, Guo L, Zhao H, Zhao J, Weng H, Zhao B. CXCR4 over-expression and survival in cancer: a system review and meta-analysis. Oncotarget 2015; 6: 5022–5040.
32. Zhang WB, Navenot JM, Haribabu B, Tamamura H, Hiramatu K, Omagari A et al. A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists. J Biol Chem 2002; 277: 24515–24521.
33. Peled A, Abraham M, Avivi I, Rowe JM, Beider K, Wald H et al. The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma. Clin Cancer Res 2014; 20: 469–479.
34. Kwong J, Kulbe H, Wong D, Chakravarty P, Balkwill F. An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells. Mol Cancer Ther 2009; 8: 1893–1905.
35. Beider K, Darash-Yahana M, Blaier O, Koren-Michowitz M, Abraham M, Wald H et al. Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo. Mol Cancer Ther 2014; 13: 1155–1169.
36. Beider K, Begin M, Abraham M, Wald H, Weiss ID, Wald O et al. CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth. Exp Hematol 2011; 39: 282–292.
37. Duan H, Zhu L, Hou J, Peng J, Xie H, Lin Y et al. Dual-affinity peptide mediated inter-protein recognition. Org Biomol Chem 2016; 14: 11342–11346.